Brief: Santhera Pharmaceuticals Holding H1 Net Loss Widens To CHF 31.8 Million
Sept 8 (Reuters) - Santhera Pharmaceuticals Holding AG
SANN.S :
* H1 NET SALES OF CHF 7.8 MILLION, OPERATING EXPENSES 16%
LOWER,
NET RESULT OF CHF -31.9 MILLION
* H1 NET RESULT OF CHF -31.8 MILLION (1H-2019: CHF -26.9
MILLION)
Source text for Eikon: ID:nGNE59hw6T
Further company coverage: SANN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million